Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tivirapine SCHEMBL3145162 | 1.00 | HTR1A (0.31) | HTR1ADRD2 | |
| Tivirapine SCHEMBL8844208 | 0.99 | HTR1A (0.31) | HTR1ADRD2 | |
| SCHEMBL7905545 | 0.90 | HTR1A (0.32) | HTR1ADRD2 | |
| SCHEMBL7905347 | 0.88 | HTR1A (0.32) | HTR1ADRD2 | |
| SCHEMBL7903407 | 0.87 | HTR1A (0.31) | HTR1ADRD2 | |
| SCHEMBL8844411 | 0.87 | PARP1 (0.33) | HTR1ADRD2 | |
| SCHEMBL8844088 | 0.86 | HTR1A (0.32) | HTR1ADRD2 | |
| SCHEMBL8844167 | 0.86 | HTR1A (0.32) | HTR1ADRD2 | |
| SCHEMBL9274799 | 0.85 | HTR1A (0.33) | HTR1ADRD2 | |
| SCHEMBL9695807 | 0.83 | HTR1A (0.30) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808743-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | claimed |
| US-20210008104-A1 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-14 | — | — | US | claimed |
| EP-3664811-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2020-06-17 | — | — | EP | claimed |
| CN-106957282-B | Viral hepatitis type b antivirotic | 诺维拉治疗公司 | 2019-08-30 | — | — | CN | claimed |
| CN-106255684-B | The method of azepan derivatives and treatment hepatitis B infection | 诺维拉治疗公司 | 2019-08-23 | — | — | CN | claimed |
| WO-2019032749-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-02-14 | — | — | WO | claimed |
| US-9938528-B2 | Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-04-10 | — | — | US | claimed |
| US-20170342411-A1 | Methods and Pharmaceutical Compositions for Treating Human Immunodeficiency Virus Type 1 (HIV-1) Infections | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2017-11-30 | — | — | US | claimed |
| EP-3230455-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2017-10-18 | — | — | EP | claimed |
| CN-104144913-B | Hepatitis B Antiviral Agent | 诺维拉治疗公司 | 2017-05-17 | — | — | CN | claimed |
| WO-1999064048-A9 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ADVANCED MEDICINE INC (US) | 2000-07-20 | — | — | WO | claimed |
| EP-1003541-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | Advanced Medicine, Inc. (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999064048-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| CN-1209875-A | Method for controlling chemotherapy in HIV-positive patients based on phenotypic drug sensitivity of human HIV strains | VIRCO NV (BE) | 1999-03-03 | — | — | CN | claimed |
| EP-0877937-A1 | METHOD OF MANAGING THE CHEMOTHERAPY OF PATIENTS WHO ARE HIV POSITIVE BASED ON THE PHENOTYPIC DRUG SENSITIVITY OF HUMAN HIV STRAINS | VIRCO N.V. (BE) | 1998-11-18 | — | — | EP | claimed |
| WO-1997027480-A1 | METHOD OF MANAGING THE CHEMOTHERAPY OF PATIENTS WHO ARE HIV POSITIVE BASED ON THE PHENOTYPIC DRUG SENSITIVITY OF HUMAN HIV STRAINS | VIRCO N.V. (BE) | 1997-07-31 | — | — | WO | claimed |
| US-5463049-A | Process for preparing enantiomerically pure imidazo[4,5,1-JK][1,4]-benzodiazepin-2(1H)-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-10-31 | — | — | US | claimed |
| US-5371079-A | Administering to inhibit replication of HIV-1 in human cells | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-06 | — | — | US | claimed |
| EP-0605499-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE IMIDAZO 4,5,1-jk] 1,4]-BENZODIAZEPIN-2(1H -)-THIONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-07-13 | — | — | EP | claimed |
| WO-1993006106-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE IMIDAZO[4,5,1-jk][1,4]-BENZODIAZEPIN-2(1H^_)-THIONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-04-01 | — | — | WO | claimed |